Introduction: Adiponectin is secreted from adipose tissue and exhibits a protective effect against cardiovascular disease; plasma adiponectin concentrations are decreased in type 2 diabetic and in hypertensive patients. Objective: The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients.
Introduction
Hypertension and type 2 diabetes are major risk factors for cardiovascular disease, and the correlation between both diseases with endothelial dysfunction, inflammation and atherosclerosis has been observed many years ago [Rubio-Guerra et al. 2010] .
Adiponectin is an adipocyte-secreted hormone (adipokine) with an insulin-sensitizing action, which stimulates the production of nitric oxide and improves endothelial function. It also has anti-inflammatory and anti-atherogenic effects [Kawanami et al. 2004] .
Low serum concentrations of adiponectin have been associated with abnormal fibrinolysis and inflammation [Patel et al. 2007 ]. Decreased plasma adiponectin levels are associated with kidney disease and albuminuria [Ahima, 2008] . Also, circulating levels of the adipokine are negatively correlated with coronary heart disease and cardiovascular mortality, and are a predictive factor for the development of hypertension and type 2 diabetes [Patel et al. 2007; Rothenbacher et al. 2005 ].
Inhibitors of the reninangiotensin system and calcium channel blockers (CCBs) have both been shown to increase adiponectin levels [Nomura et al. 2007; Furuhashi et al. 2003 ]; we hypothesized that the combination of an angiotensin-converting enzyme inhibitor (ACEI) plus a CCB would be more effective than monotherapy with either drug at increasing circulating adiponectin levels in type 2 diabetic hypertensive patients.
The aim of this work was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients.
Methods
A total of 40 hypertensive type 2 diabetic patients with never-treated hypertension, referred from primary care clinics, were included. They were randomly assigned to two groups of 20 patients each. One group received FDTV (T2 mg+ Verapamil 180 mg) once a day; the other one received T2 mg once a day. Study drugs were administered for 3 months in both groups. Patients were evaluated monthly for blood pressure (BP), heart rate, fasting serum glucose and adverse events. BP was recorded in triplicate with a mercurial sphygmomanometer in the sitting position after a 5-minute rest and at 3-minute intervals; an average of the three measurements was recorded.
In all of the subjects, adiponectin levels were measured at the beginning and the end of the study, in duplicate, by commercial enzymelinked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN). All venous samples were collected in the morning, after 12 h overnight fast.
Intra-assay precision (precision within an assay) for adiponectin was 19.8 ng/ml, whereas interassay precision (precision between assays) was 12.5 ng/ml, fasting glycemia (glucose oxidase) also was measured from that sample.
Patients with any of the following diagnoses were excluded from the study: decompensate diabetes mellitus (fasting blood glucose >250 mg/dl); secondary hypertension; heart, hepatic, or renal failure; evidence of valvular heart disease; heart block or cardiac arrhythmia; acute coronary syndrome or cerebrovascular disease within the 6 months before the study's initiation; autoimmune disease, pregnancy; urinary tract infection, fever or a history of alcohol abuse and/or psychotropic drugs.
The patients were not allowed to use any of the following drugs: any other type of antihypertensive than the study medication, statins, glitazones, tricyclic antidepressives and/or monoamine oxidase (MAO) inhibitors, or any other drug for research purposes within 30 days of the study's initiation.
The study was conducted with the approval of the Research and Medical Ethics Committee of our hospital, in accordance with the Helsinki declaration. Participants gave informed, written consent before their inclusion in the study protocol.
Statistical analysis
Data are presented as the mean±standard deviation. Statistical analysis was performed by ANOVA, and p < 0.05 was considered significant.
Results
The basic features of both groups are described in Table 1 .
All patients experienced a significant reduction of BP (in the FDTV group it went down from 174±12/94±8 mmHg to 131±9/79±4 mmHg, p < 0.005, and in the T group from 176±15/ 92±13 mmHg to 134±12/81±7 mmHg, p < 0.005).
Both therapeutic regimens increased the levels of adiponectin, However, FDTV produces a higher increase (p < 0.05) in the levels of the adipocytokine (8.15±4.6 to 10.96±5.6 mg/ml) when compared with the T treatment (7.64±3.8 to 8.92±4.4 mg/ml) ( Figure 1) .
No patient had a significant change in heart rate, in the FDTV group the heart rate went from 76±4 bpm to 75±5 bpm; and in T group from 76±7 bpm to 76±5 bpm (p > 0.05).
No patient suffered adverse events. The number of capsules returned by the patients on each visit was <5% of those dispensed.
Discussion
According to the guidelines, in the management of hypertension in patients with type 2 diabetes the primary antihypertensive drug should be an inhibitor of the reninangiotensin system, either with ACEI or angiotensin receptor antagonists. However, for many patients, one antihypertensive agent is not sufficient to achieve the recommended goals. In these situations, a second drug, usually a CCB or a thiazide-like diuretic, is necessary [Bakris et al. 2008] . In this study we found that trandolapril and its fixed-dose combination with the CCB verapamil increased circulating adiponectin levels in type 2 diabetic patients with hypertension; however, FDTV produces a greater increase in the circulating levels of the adipokine than trandolapril alone, despite the same degree of BP reduction. It is important to say that in our work, the circulating levels of the adipokine were measured in duplicate, so intraindividual variation was taken into account when statistical analysis was performed. It is also relevant to say that our patients were thiazolidinedione-naïve and statin-naïve, because both drugs have been shown to raise circulating levels of adiponectin [Kawanami et al. 2004; Patel et al. 2007] .
Several studies had shown an inverse relation between adiponectin and the development of vascular damage and cardiac disease, by reducing adhesion molecules and the transformation of macrophages to foam cells, and limiting atherosclerotic plaque progression [Hopkins et al. 2007; Patel et al. 2007] . We have reported that FDTV reduces the circulating levels of vascular-cellular adhesion molecule-1 (VCAM-1) to a greater extent than trandolapril as monotherapy [Rubio-Guerra et al. 2008 ]. This finding, and also the increase in the adiponectin level found in this paper (that may mediate the reduction in VCAM-1 levels), are unrelated to the decrease in BP observed. Taken in conjunction, these results shown that FDTV could have a dual effect in type 2 diabetic hypertensive patients: an antihypertensive action accompanied by an anti-inflammatory effect that might give increased protection to target organs. In fact, the increase in adiponectin levels with FDTV that we found could have prognostic implications; certainly, high concentrations of the adipokine are associated with lower risk of coronary heart disease in humans [Hopkins et al. 2007 ]. Thus, the use of antihypertensive agents that raise the circulating levels of the hormone may lead to benefits not only related with the decrease in the BP values. Abnormal glucose metabolism is diagnosed in about 60% of hypertensive patients [Garcia-Puig et al. 2006 ], and several studies have shown that blockade of the reninangiotensin system improves glucose tolerance [Opie and Schall, 2004] , and a beneficial effect of CCBs on glucose homeostasis has also been reported [Taylor et al. 2006 ]. Thus, it is considered that combination therapy comprising an inhibitor of the reninangiotensin system plus CCB may reduce insulin resistance [Rubio-Guerra et al. 2009 ].
In the Anglo Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), the amlodipineperindopril group had a significantly lower incidence of newonset diabetes compared with the atenololbendroflumethiazide group [Dahlöf et al. 2005] , the amlodipineperindopril regimen also was more effective than atenololthiazide group in decreasing fatal and nonfatal stroke, total cardiovascular events and all-cause mortality (all of these were secondary end points). Also, in the International Verapamil SR/Trandolapril Study (INVEST), the verapamiltrandolapril group had a significantly lower incidence of new-onset diabetes compared with the atenololtrandolapril group [Pepine et al. 2003 ]. These effects would not be entirely explained by better control of BP.
In the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), FDTV reduced the risk of new-onset diabetes when compared with the combination of losartan with a thiazide diuretic in hypertensive patients with impaired glucose tolerance [Bakris et al. 2006 ], although the changes in glucose tolerance in the STAR trial were explained by a worsening of glucose tolerance due to the thiazide use.
The differences in glycemic metabolism seen in the previous trials might be due, at least partially, to the increase on adiponectin levels; this requires further evaluation.
Adiponectin treatment enhances nitric oxide production and improves endothelial function, the adipokine also lowers plasma glucose levels and leads to a reduction in plasma free fatty acids and triglycerides without changes in body mass index [Wang and Scherer, 2008; Hopkins et al. 2007] , as changes in lifestyle do not modify adiponectin levels, and hypoadiponectinemia is only reversed with pharmacological treatment [Patel et al. 2007 ]. Therapies that increase the levels of this adipokine, as the combination of an inhibitor of the reninangiotensin system plus CCB, as used in this study, might lead to clinical and metabolic benefits, similar to those in the above-mentioned ASCOT-BPLA, INVEST and STAR trials
We did not find significant changes in mean BP reduction, perhaps because both treatments produced an important decrease in those values. However, it was interesting that heart rate did not change with the use of the drug combination, because this parameter usually is reduced with verapamil. We previously reported this observation (unchanged heart rate) in hypertensive patients; this may be due to an idiosyncratic response of Mexican people [Rubio-Guerra et al. 2008] .
Conclusion
Our results show that both treatments increase adiponectin levels; however, FDTV produces a greater increase in this adipokine than trandolapril alone.
This could explain some beneficial effects of this fixed-dose combination that are not related to its antihypertensive effects, and that these effects, which in turn lead to a greater target-organ protection, might be via an anti-inflammatory action.
It is possible that the favorable metabolic effects seen with this fixed-dose combination, and that some of the pathways for the risk reduction of new-onset diabetes with the use of inhibitors of the reninangiotensin system and CCBs may be mediated by the reduction of resistin levels.
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